3rd-gen-CD19-CAR

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug Name3rd-gen-CD19-CAR

Drug Alias Name3rd-gen-CD19-CAR

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-CellLeukemia, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesGenetix Biotherapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesGenetix Biotherapeutics Inc Celgene Corp

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellLeukemia, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A